Share this page

Treating Anal Cancer Precursor Lesions Reduces Cancer Risk for People Living With HIV.


ANCHOR Study Halted Due to Therapy’s High Success Rates.

Treating precursor anal cancer lesions can significantly reduce the risk of progression to full blown anal cancer among people living with HIV, according to results of a large, phase 3 study led by researchers at UC San Francisco.

In a randomized clinical trial with 4,446 participants, known as the Anal Cancer/HSIL Outcomes Research (ANCHOR) study, researchers found that by removing high-grade squamous intraepithelial lesions (HSIL), chances of progression to anal cancer were significantly reduced.

The trial is the first to show such findings and was performed at 21 clinical sites around the United States. Results are being prepared for peer-reviewed publication and are being shared now because of the public health importance of the findings.

See full UCSF press release in our Newsletter section for more details...!